The Age of Longevity: Medicine as a Demographic Tool
Andrey Antonov, founder and CEO of KREDO LLC's digital ecosystem for medical device registration, discusses how modern medicine is shaping demographics. Over the past century, active life expectancy in developed countries has increased significantly — often viewed simply as a natural result of progress.
Source: "Inpharm" publication (original publication, in Russian)
From treatment-focused medicine to life-cycle management
The traditional healthcare system was built around treating problems that had already occurred. The modern approach involves managing a person's entire life cycle: the emphasis shifts to prevention, early diagnosis, chronic-disease management, rehabilitation, and functional recovery. For governments, this allows better control over the burden on the healthcare system; for businesses, it extends the period of active working life.
One example is Singapore's primary-care reform, implemented through its Healthier SG initiative, aimed at disease prevention and effective chronic-condition management. The program assigns each patient a family doctor and draws on a broad network of primary-care providers. According to Singapore's Ministry of Health, more than 1,000 general practitioners have already joined the program, and the number of enrolled residents has surpassed 700,000.
In Russia, the Ministry of Health has run a pilot project on remote monitoring of indicators such as blood pressure, pulse, and glucose levels for patients with chronic conditions, as part of the "Personal Medical Assistants" initiative. The monitoring was integrated into clinical workflows rather than remaining at the level of consumer fitness devices.
Lifestyle matters more than technology — but is hard to scale without it
From a scientific and practical standpoint, a significant increase in healthy life expectancy comes from establishing a certain lifestyle: balanced nutrition, physical activity, quality sleep, and effective stress management.
In the UK, for example, the Healthier You: NHS Diabetes Prevention Programme (NHS DPP) has demonstrated a population-level effect: according to studies and NHS England materials, participants who completed the program showed a reduced risk of developing type 2 diabetes, along with a system-wide drop in new diagnoses.
In Moscow, the "Moscow Longevity" project operates as a comprehensive infrastructure initiative supporting active aging. Unlike one-off events, it's a large-scale city-wide system for engaging older residents in physical, educational, and social activity. Russia's public-opinion research center VTsIOM conducted a separate analysis of the project's social effects, assessing its role as a catalyst for shaping demand and supply as well as its influence on shifting public perceptions of old age.
The longevity economy and 5P medicine
The healthcare market is shifting from a model of treating isolated episodes to an integrated system for managing risk and patients' quality of life. In this paradigm, the concept of 5P medicine (predictive, preventive, personalized, participatory, precision) has become practically relevant, reflecting the transformation of clinical practice and healthcare systems toward data analysis, early diagnosis, and individualized care pathways. How well these approaches can actually be implemented depends directly on a healthcare system's technological base and the pace of its development.
Singapore's Healthier SG project, mentioned above, implements an institutional strategy for prevention and chronic-disease management through primary care and long-term doctor-patient relationships. This systemic transformation is examined in detail both in academic reviews and in materials from Singapore's Ministry of Health.
As part of Russian government policy, the federal "Older Generation" project (under the national "Demography" program) provides for a set of measures aimed at increasing the population's healthy life expectancy. Key tools include routine health checkups, preventive medical examinations, expanding the network of geriatric care, building geriatric centers, and operating a long-term care system. According to TASS, the corresponding infrastructure is being developed and specialists in the field are being trained.
Technology benchmarks
Longevity-related technology development includes long-cycle, heavily regulated fields such as cellular reprogramming, the use of AI in drug development, genetic techniques, senolytics, and aging biomarkers. These technologies matter to healthcare not just because they're novel — they're an indicator of where clinical platforms, diagnostics, and pharmaceuticals are headed over the next 5 to 15 years. Among other players, Altos Labs has emerged as one of the best-funded biotech ventures: Chemical & Engineering News (a publication of the American Chemical Society) reported the company launched with roughly $3 billion in funding and a strategic focus on cellular rejuvenation programming.
Looking at the industrial medical-device sector, Russia has seen growing supply volumes and an expanding range of domestically produced equipment. According to state corporation Rostec, tens of thousands of units of medical equipment were delivered to healthcare organizations in 2024, including pacemakers and an expanding line of cardiology devices. For the active-longevity field, this is a meaningful indicator: cardiology and chronic-disease management remain key areas driving demand as the population ages.
The Russian market: a pragmatic approach from clinics, and opportunities for manufacturers
Against this backdrop, Russia's healthcare market is particularly interesting, since longevity strategies there are taking shape under structural and regulatory constraints. In practice, healthcare organizations' choices are driven not by ideology but by economic sustainability: priority goes to clinical validity, service quality, integration with digital health systems, supply predictability, and regulatory transparency. For private clinics and healthcare networks, these factors are becoming the foundation for long-term patient-relationship models and continuous-care services.
This approach has become especially relevant amid tightening sanctions and logistics constraints, driving growing demand for solutions in chronic-patient monitoring, rehabilitation, and functional diagnostics — areas directly tied to extending the population's active life.
In the United States, Remote Patient Monitoring (RPM) has been integrated into clinical practice through formal billing and reimbursement rules. The official HHS telehealth portal sets requirements and limits for billing RPM services, including a minimum data-collection period and a "one biller per patient" rule. This illustrates how government regulation can turn monitoring technology into a billable medical service.
In Russia, remote-monitoring practice is moving from pilot projects to management decisions at the regional level. The newspaper Kommersant, for instance, analyzed the results of a project in the Udmurt Republic, run jointly by the regional Ministry of Health and SberZdorovye, where a significant share of patients with hypertension and diabetes saw their clinical indicators normalize.
Conclusion
Longevity has stopped being a passing trend and has become an important element of management strategy — both for corporations across sectors and at the level of government. For governments, longevity is an effective tool for ensuring demographic and economic stability by extending the population's healthy, productive lifespan.
For businesses, longevity means an opportunity to extend employees' active working years and reduce the costs associated with chronic disease. Clinics are shifting toward continuous-care models, and medical device manufacturers are finding new opportunities in monitoring, rehabilitation, cardiology, and digital health.
A necessary condition for the success of longevity strategies in the Russian market is a solid evidence base, a high level of service, and regulatory transparency. Without these components, longevity risks remaining a marketing term rather than an effective demographic tool — and longevity initiatives risk staying a collection of disconnected programs with no measurable demographic impact.
Andrey Antonov, Founder and CEO of KREDO LLC
Frequently asked questions
- How is modern healthcare different from the traditional model?
- The old system was built around treating problems that had already occurred, whereas the modern approach manages a person's entire life cycle: prevention, early diagnosis, chronic-disease management, rehabilitation and functional recovery. For governments this gives better control over the burden on the healthcare system, and for businesses it extends the period of active working life.
- What does Singapore's Healthier SG programme involve?
- It is a primary-care reform aimed at disease prevention and effective management of chronic conditions: every patient is assigned a family doctor and the programme draws on a broad network of primary-care providers. According to Singapore's Ministry of Health, more than 1,000 general practitioners have already joined and the number of enrolled residents has surpassed 700,000.
- How are patients with chronic conditions monitored in Russia?
- The Ministry of Health has run a pilot project on remote monitoring of blood pressure, pulse and glucose levels as part of the "Personal Medical Assistants" initiative. The monitoring was integrated into clinical workflows rather than remaining at the level of consumer fitness devices.
- What is 5P medicine?
- It stands for predictive, preventive, personalized, participatory and precision medicine. The concept reflects the transformation of clinical practice and healthcare systems toward data analysis, early diagnosis and individualized care pathways.
- Which technologies shape the future of longevity research?
- Long-cycle, heavily regulated fields such as cellular reprogramming, the use of AI in drug development, genetic techniques, senolytics and aging biomarkers. They indicate where clinical platforms, diagnostics and pharmaceuticals are headed over the next 5 to 15 years; Altos Labs, for example, launched with roughly $3 billion in funding and a focus on cellular rejuvenation programming.
